EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy

Takeshi Sasaki, Shinichiro Higashi, Kouhei Nishikawa, Koji Iinuma, Keita Nakane, Tomoki Taniguchi, Yuta Sano, Aika Matsuyama, Kaori Ozawa, Kosuke Tochigi, Masataka Tamura, Yasuaki Kubota und 3 weitere

International Journal of Clinical Oncology · 2026

DOI: 10.1007/s10147-026-03115-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Takeshi Sasaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Neutrophils, Carcinoma, Renal Cell, Lymphocytes, Kidney Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mie University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study investigated whether neutrophil-to-lymphocyte ratio (NLR) kinetics, including changes within the first week after the initiation of first-line combination immunotherapy, are associated with overall survival (OS) in patients with advanced renal cell carcinoma (aRCC).

Methods

Consecutive patients with aRCC treated with first-line immune checkpoint inhibitor combination therapy at 12 Japanese institutions were included in this retrospective study. The NLR was assessed at baseline (BL), within 7 days (D7), and 1 month (M1) after treatment initiation. Patients were classified into three groups according to NLR at BL and at D7 as follows: BL NLR low (< 3), NLR high-low (BL NLR ≥ 3 and D7 NLR < 3), and NLR high-high (BL NLR ≥ 3 and D7 NLR ≥ 3) groups.

Results

In total, 198 patients were included in the study, with a median follow-up of 18.0 months. The median NLR changed during follow-up at BL, D7, and M1 (BL, 3.28; D7, 3.23; M1, 2.74). OS stratified by NLR at each time point was significant at BL and D7, but not at M1. Among patients with BL NLR ≥ 3 (55%, n = 109), 26 patients (24%) had D7 NLR < 3. The 2 year OS rates were 83.7, 85.5, and 66.0% for patients in the low-, high-low-, and high-high groups, respectively. Multivariate analysis revealed that high NLR was an independent risk factor associated with worse OS.

Conclusions

The combination of BL NLR and D7 NLR identified high-risk patients with aRCC treated with first-line immune checkpoint inhibitor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeutrophilsCarcinoma, Renal CellLymphocytesKidney NeoplasmsImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedImmunotherapyAged, 80 and overPrognosisAdult

Stichwörter der Autor:innen

ImmunotherapyNeutrophil-to-lymphocyte ratioOverall survivalRenal cell carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.
  • Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan.
  • Department of Urology, Yokkaichi Municipal Hospital, Yokkaichi, Mie, Japan.

Förderung

  • Mie University

Zitieren

APA

Sasaki, T., Higashi, S., Nishikawa, K., Iinuma, K., Nakane, K., Taniguchi, T., Sano, Y., Matsuyama, A., Ozawa, K., Tochigi, K., Tamura, M., Kubota, Y., Akamatsu, S., Koie, T., & Inoue, T. (2026). Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03115-x

Vancouver

Sasaki T, Higashi S, Nishikawa K, Iinuma K, Nakane K, Taniguchi T, et al. Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03115-x

BibTeX
@article{Sasaki2026,
  author = {Sasaki, Takeshi and Higashi, Shinichiro and Nishikawa, Kouhei and Iinuma, Koji and Nakane, Keita and Taniguchi, Tomoki and Sano, Yuta and Matsuyama, Aika and Ozawa, Kaori and Tochigi, Kosuke and Tamura, Masataka and Kubota, Yasuaki and Akamatsu, Shusuke and Koie, Takuya and Inoue, Takahiro},
  title = {Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1007/s10147-026-03115-x}
}
Kostenlos starten →